Oncologists and top-upsBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b2530 (Published 23 June 2009) Cite this as: BMJ 2009;338:b2530
- Virginia J Warren, public health physician1
- 1Bupa House, London WC1A 2BA
Oncologists believe that their patients would benefit from licensed drugs that either are not yet the subject of guidance from the National Institute for Health and Clinical Excellence (NICE), or not approved by NICE.1 Analysis of requests for discretionary payments for off-label treatment for Bupa (British United Provident Association) members with malignant disease also shows that they …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial